Feb 12, 2020
Global Bell's Palsy Incidence Assessment by Ethnicity & Geography, 2019-2029
Jan 13, 2020
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia
Nov 07, 2019
Spinocerebellar Ataxia (SCA) Epidemiology Forecast to 2028: Assumptions and Rationale, Total Prevalent Population, Total Diagnosed Cases, Type-Specific Prevalence
Oct 08, 2019
Need to Balance Guides Development of Limb-Body Coordination
Jul 31, 2019
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
May 07, 2019
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
Mar 14, 2019
Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
Mar 14, 2018
Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I
Feb 05, 2018
Jupiter Orphan Therapeutics in Process to Submit IND for MPSI and Other Indications
Dec 05, 2017
Friedreich's Ataxia- Treatment Algorithm and Competitive Landscape 2017
Nov 27, 2017
Global Friedreich's Ataxia (FRDA) Therapeutics Pipeline Analysis 2017 - Key Players are Cardero Therapeutics, Edison Pharmaceuticals & Retrotope
Oct 18, 2017
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
Oct 02, 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Aug 22, 2017
Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia
Aug 07, 2017
Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017
Aug 03, 2017
Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia